# Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

> **NCT05863234** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hiroshima University Hospital** · enrollment: 7 (estimated)

## Conditions studied

- Aggressive NK Cell Leukemia

## Interventions

- **DRUG:** PPMX-T003

## Key facts

- **NCT ID:** NCT05863234
- **Lead sponsor:** Hiroshima University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863234, "Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05863234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*